# Biofourmis acquires Biovotion and inks commercialization deal with Novartis

Biofourmis acquired Swiss wearable biosensor company Biovotion for cash and equity, including its Everion device and patents. Separately, Biofourmis partnered with Novartis for commercial rollout of a heart failure management platform using AI and the Everion sensor, starting in Asia.

- Type: Acquisition
- Announced: 2019-11-18
- Where: Zürich, Switzerland, Switzerland
- Status: completed
- Products: wearable biosensors, AI-based monitoring platform, heart failure management platform
- Sectors: [Medical Devices](https://endata.com/sectors/medical-devices.md)

## Companies

- [Novartis](https://endata.com/companies/32041.md) (partner)
- [Biofourmis](https://endata.com/companies/43363.md) (acquirer)
- [Biovotion](https://endata.com/companies/43364.md) (target)

## Sources

- [mobihealthnews.com](https://www.mobihealthnews.com/news/biofourmis-acquires-biovotion-inks-commercialization-deal-novartis), 2019-11-18: "The acquisition will include Biovotion's clinical grade-wearable technology Everion, as well as its entire portfolio and pipeline, team, clients, partners and patents."

---
Data from Endata (https://endata.com/). Announcements are summarized from public sources and may be incomplete; check the linked originals.